Pyrazinamide Oral: Tuberculosis Dosing
Pyrazinamide guidance for tuberculosis in combination therapy, with renal adjustment and hepatotoxicity precautions.
Also searched as
Source reviewed
June 2021
Guide category
Oral drugs
Safety boundary
Prescription medicine information for clinician-guided use.
Kenza Health Hub presents this medicine page as structured health education. Check dose, route, interactions, pregnancy or breast-feeding considerations, and local protocol with a qualified clinician or pharmacist. Read our medical editorial policy.
Therapeutic action
First-line antituberculosis antibacterial with sterilising and bactericidal activity.
Indications
Tuberculosis, in combination with other antituberculosis antibacterials.
Forms and strengths
- 400 mg tablet.
- 150 mg dispersible tablet.
Dose
- Child under 30 kg: 35 mg/kg once daily, usual range 30 to 40 mg/kg.
- Child 30 kg and over and adult: 25 mg/kg once daily, usual range 20 to 30 mg/kg.
- Do not exceed 2 g daily.
- Patient with renal impairment: 25 mg/kg 3 times weekly.
Duration
According to protocol.
Contra-indications, adverse effects, precautions
- Do not administer to patients with hypersensitivity to pyrazinamide, severe hepatic impairment, or severe gout.
- May cause gout and arthralgias, hepatotoxicity, photosensitivity, rash, gastrointestinal disturbances, and hypersensitivity reactions.
- Monitor liver function in patients with known hepatic disease.
- If signs of hepatotoxicity such as jaundice develop, pyrazinamide should be discontinued until symptoms resolve.
- Pregnancy: no contra-indication.
- Breast-feeding: no contra-indication.
Source
MSF Essential drugs practical guidelines (January 2026)
This page combines source-derived medicine reference sections with Kenza editorial context, while leaving out the Storage and Remarks sections from the source batch.
Rate this guide
Be the first to rate this guide.